3.11
+0.08(+2.64%)
Currency In USD
Address
2042 Corte Del Nogal
Carlsbad, CA 92011
United States of America
Phone
760 918 9165
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
June 23, 2015
| Name | Title | Pay | Year Born |
| Mr. Kevin A. Richardson II | Interim Chief Executive Officer, Interim Chief Financial Officer & Chairman of the Board | 0 | 1968 |
| Mr. Christopher L. Lotz | Vice President of Finance & Corporate Secretary | 578,555 | 1965 |
| Mr. Michael S. Poirier | Chief Operating Officer | 632,698 | 1956 |
| Mr. Robert W. Campbell Becher | President & Director | 0 | 1971 |
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.